Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Polled Review Staff On Avandia REMS Changes

Dec 02 2013

• By Sue Sutter

Related Content

FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training

Nov 26 2013

Shared REMS Systems Show Challenges Of Standardization – Could PDUFA V Help?

Jul 22 2013

<em>Avandia</em> Committee Gives Split Vote To Drug, But FDA Clear Winner

Jun 10 2013

<em>Avandia</em> Review Endorsement Aided By Good Data, Cultural Shift On Safety

Jun 17 2013

GSK’s DoJ Settlement Links Executive Bonus To Continued Compliance

Jul 09 2012

Avandia REMS Limits Access To Mail Order Pharmacies Beginning In November

May 18 2011

FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

Jul 19 2010

Will CV Verdicts For <em>Onglyza</em>, <em>Nesina</em> Cause FDA To Change Its Tune On Antidiabetic Safety?

Sep 09 2013

FDA Drug Review, Surveillance Offices Agree To Share Safety Authority

Jul 07 2008

FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Sep 27 2010

Related Companies

GSK plc

Takeda Pharmaceutical Co. Ltd.

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Safety Risk Management BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window